Resideo Grid Services RGS
Total Consideration
$78.8M
Purchase-Price Allocation
Goodwill
$45.1M
2 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 1.40% | -1.00% | 1.00% | 3.70% | 3.20% | 3.80% |
| Foreign Rate Differential | — | 0.00% | 0.00% | 1.60% | 1.80% | 1.80% |
| Other Adjustments | — | — | — | 0.00% | 0.00% | 0.30% |
| R&D Tax Credits | 9.40% | 17.70% | 16.50% | 7.20% | 10.00% | 6.70% |
| FDII Deduction | — | 1.70% | 7.00% | 4.40% | 3.40% | 0.00% |
| Nondeductible Expenses | 0.00% | 1.90% | 1.80% | 2.90% | 1.20% | 1.80% |
| Valuation Allowance Change | 1.30% | 1.10% | 0.40% | 0.00% | 0.00% | 0.00% |
| Tax Law Change | -0.20% | 0.00% | — | 0.00% | 0.00% | 0.00% |
| Effective Tax Rate | 4.40% | -11.10% | 1.70% | 17.90% | 13.60% | 22.60% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $3.5M | −$5.1M | $962.0K | $17.5M | $19.3M | $37.6M |
| Income Taxes Paid (Cash) | $7.4M | $4.1M | $7.5M | $64.6M | $68.2M | $45.4M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$78.8M
Purchase-Price Allocation
Goodwill
$45.1M
Total Consideration
$27.1M
Purchase-Price Allocation
Goodwill
$23.5M
Deferred Tax Liability
$1.5M
Purchase-Price Allocation
Goodwill
$3.1M
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).